Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HJ197
- Development stage
- Unknown
- Lead developer
- 成都华健未来科技
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HJ197 is a potent and highly selective small molecule inhibitor of Fibroblast Growth Factor Receptor 4 (FGFR4), developed by Chengdu Huajian Future Technology. It is designed to target the FGF19-FGFR4 signaling pathway, which is frequently dysregulated in hepatocellular carcinoma (HCC), particularly in cases characterized by FGF19 overexpression. By specifically binding to and inhibiting FGFR4, HJ197 disrupts downstream signaling cascades that promote tumor cell proliferation, migration, and survival. The drug is currently undergoing Phase 1 clinical evaluation in patients with advanced solid tumors, with a primary focus on HCC.
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)
Beyond the preview
Go deeper on HJ197.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HJ197.